CN1299656A - Asthma treating medicine and its production process - Google Patents
Asthma treating medicine and its production process Download PDFInfo
- Publication number
- CN1299656A CN1299656A CN 00114245 CN00114245A CN1299656A CN 1299656 A CN1299656 A CN 1299656A CN 00114245 CN00114245 CN 00114245 CN 00114245 A CN00114245 A CN 00114245A CN 1299656 A CN1299656 A CN 1299656A
- Authority
- CN
- China
- Prior art keywords
- asthma
- medicine
- treatment
- radix
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The Chinese medicine for curing asthma is made by 12 Chinese medicinal materials of pungent oleaster leaf, biota leaf, hemp-leaved vitex leaf, perilla stem, ginseng, aquliaria leaven and others through a certain preparation process according to its prescription. It possesses the functions of downbearing qi, calming panting, expelling phlegm and suppressing cough, and can obtain good therapeutic effect for curing bronchial asthma, allergenic asthma, spasmodic asthma and congenital asthma.
Description
The present invention relates to a kind for the treatment of asthma medicine and production method thereof.
Asthma, be in a kind of common disease, particularly old people sickness rate more so.But no matter be Chinese medicine at present, or Western medicine, all there is the shortcoming that the time of relievining asthma is not long, the effect of relievining asthma is not strong.
Purpose of the present invention is exactly the shortcoming for the weak effect of relievining asthma that overcomes present suppressing panting calming medicine, provides a kind of instant effect, the time of relievining asthma is long breathes heavily the good medicine of heavy breathing therapeutic effect.
The present invention realizes like this.
The present invention adopts following 12 herbal medicines:
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Wherein the ratio of each medicine is for being 1 weight portion with a medicine in the prescription, and all the other amount of drug are 1/5～5 times of weight portion.Get above-mentioned each medicine full dose, become oral powder through grinding and processing; Or get above-mentioned each medicine full dose, and to add water to submerge the back and extract one to three time, merge extractive liquid, concentrates, and further adds adjuvant (as Icing Sugar) and granulates, and makes electuary; Electuary adds conventional tablet adjuvant (as starch, Icing Sugar, dextrin, magnesium sulfate, Pulvis Talci) by tablet machine, makes tablet.Also can be processed into pharmaceutics what its peroral dosage form of taking up an official post.
Bulbus Fritillariae Cirrhosae of the present invention can replace with Bulbus Fritillariae Thunbergii.
Dosage and instructions about how to take medicine: oral, adult's disease the lighter once obeys 2.25 grams, and disease heavy person 4.5 restrain, and disease the lighter once obeyed 1 to 2 gram in 15 to 12 years old, heavy person's 2 to 3 grams of disease, and disease the lighter once obeyed 1 gram in 11 to eight years old, and heavy person's 1.5 grams of disease were once obeyed 0.5 to 1 and are restrained in seven to four years old.Obey secondary every day, sooner or later service once after meal.
The all medicines of the present invention share: mainly be in harmonious proportion lung kidney spleen and remove bronchospasm, lung gets foster clearly, and kidney is can improving inspiration by invigorating kidney-QI solid dirty, and spleen must perfect fortuneization, and mechanism of qi must be transferred, and impels its expectorant to disappear, and coughs and ends, and falls against gas, and dyspnea with rapid respiration is put down, thereby reaches the effect of asthma healing.
Medicine of the present invention has sending down the abnormal ascending QI, and relieving asthma, eliminate the phlegm, the effect of antitussive, mainly curing bronchial asthma, simultaneously to anaphylaxis, asthma such as spastic, congenital all has excellent curative.Its instant effect, taking convenience, the time of relievining asthma is long, physical rehabilitation is fast, takes medicine one time, and the time of relievining asthma can reach 12 hours.
The invention will be further described below in conjunction with embodiment.
Embodiment 1
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Weight fraction such as each medicine.
Become oral powder through grinding and processing.
Embodiment 2
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Each medicine weight ratio is 1: 5: 2: 1/5: 1/3: 1: 2: 3: 4: 3: 2: 5.
The full dose of getting it filled is added water to submerge the back and is extracted totally one～three time, and merge extractive liquid, concentrates, and makes every milliliter of oral liquid that contains raw medicinal herbs 1 gram.
Embodiment 3
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Each medicine weight ratio is: 5: 1: 1/5: 1: 3: 2: 1: 1/3: 1/4: 3: 5: 2.
Get each medicine full dose, add water to submerge the back and extract one～three time, merge extractive liquid, adds Icing Sugar and granulates, and makes electuary, packing.
Embodiment 4
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Each medicine weight ratio is: 1/5: 1/5: 5: 5: 1: 1/3: 1/2: 1: 1: 1/3: 1: 1/5.
Get each medicine full dose, add water to submerge the back and extract one～three time, merge extractive liquid, adds starch and granulates, and further adds magnesium sulfate, and Pulvis Talci is pressed into tablet through tablet machine.
Embodiment 5
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Each medicine anharmonic ratio is 2: 1: 1/2: 3: 1/5: 5: 5: 1/5: 5: 1/5: 1/5: 1, get each medicine full dose, and become oral powder through grinding and processing.
Embodiment 6
Folium Elaeagni Cacumen Platycladi Folium Viticis Negundo Caulis Perillae Radix Ginseng Lignum Aquilariae Resinatum
Rhizoma Dioscoreae Radix Glycyrrhizae Bulbus Fritillariae Cirrhosae Cortex Magnoliae Officinalis Ramulus Cinnamomi Radix Et Rhizoma Rhei
Each medicine weight ratio is 3: 2: 1/5: 1/2: 5: 1/5: 1/5: 5: 1/5: 5: 1/2: 3, get each medicine full dose, and make oral granule by the production method of embodiment 3.
Embodiment 7
Change the Bulbus Fritillariae Cirrhosae among the embodiment 6 into Bulbus Fritillariae Thunbergii, make powder by the method for embodiment 5.
Get embodiment 1 and carry out relevant pharmacodynamics test and toxicological experiment,
Reagent and material:
1. embodiment 1, when integral experiment, with the suspension of its distilled water; During isolated experiment, with its distilled water leachate, centrifugal (2000 rev/mins) are got supernatant and are used for experiment.
2. histamine phosphate.
3. aminophylline injection.
4. mice, Cavia porcellus.
Method and result
One, the influence of 1 pair of isolated tracheal smooth muscle of embodiment (tracheal volume method)
Get the Cavia porcellus about body weight 350g, hit hindbrain to dusk, cut cervical region immediately open, separate trachea, take off below thyroid, put into nutritional solution and wash down the tube chamber content to the complete trachea section of trachea lower end crotch with wooden stick.Trachea Duan Yiduan is pricked at capillary tip.The other end is pricked on U type pipe.Another termination one syringe of U type pipe, interior suction have isolated tracheal nutritional solution (sodium bicarbonate 1.0g, sodium dihydrogen phosphate 0.32g, magnesium chloride 0.42g, glucose 1.0g, calcium chloride 0.4g is made into 1000ml for sodium chloride 8.0g, potassium chloride 0.2g).Nutritional solution is slowly injected in the trachea, discharging endotracheal bubble, and regulate capillary tube liquid level height.Trachea and connecting device are put into the bath that fills the 15ml nutritional solution, and bath temperature remains on 37 ± 1 ℃.At bath bottom aerating oxygen, about 15～20 bubbles of per minute (min) are advisable.Allow trachea stablize with this understanding 20 minutes.During experiment,, shrinks the medicinal liquid that adds then liquid level rising (note is made mm) in the capillary tube when making trachea; When the medicinal liquid that adds makes the trachea diastole, then in the capillary tube liquid level descend (note does-mm).
During experiment, in bath, add earlier the 0.1ml of histamine phosphate (0.5mg/ml), observe and write down millimeter (mm) number of liquid level change in the 5min, add distilled water or embodiment 1 test liquid or aminophylline test liquid immediately, observe and write down the mm number of liquid level change in the 5min.The result lists table 1 in.
The influence of 1 pair of isolated tracheal smooth muscle of table 1. embodiment (tracheal volume method)
| Group | Medicine final concentration (mg/ml) | Liquid level changes | The P value |
| Distilled water | ????0.1±0.1 | ||
| Embodiment 1 | ????5.4 | -17.8±4.7 | ????＜0.001 |
| Embodiment 1 | ????3.6 | -12.3±3.0 | ????＜0.001 |
| Aminophylline | ????0.8 | -19.1±3.1 | ????＜0.001 |
Table 1 explanation, embodiment 1 and aminophylline have tangible diastole effect to isolated tracheal smooth muscle, and the diastole effect of embodiment 1 is tangible dose-effect relationship.
Two, the antiasthmatic effect of 1 pair of Cavia porcellus drug-induced asthma of embodiment
Get 40 of 160-200g Cavia porcelluss, be divided into 4 groups at random, every group 10, each organizes Cavia porcellus po distilled water, embodiment 1 (large and small dosage group), ip aminophylline respectively, after 1 hour, puts into bell glass respectively, histamine phosphate (2mg/ml) is sprayed in the cover, Cavia porcellus through promptly producing asthma reaction one period incubation period, is as the criterion to have a convulsion, to fall after sucking histamine.Record spraying begin to time that symptom occurs as latent time, surpass 6min and calculated with 360 seconds.The results are shown in table 2.
The antiasthmatic effect of 1 pair of Cavia porcellus drug-induced asthma of table 2. embodiment
| Group | Dosage (mg/kg) | Asthma reaction incubation period (s) | The P value |
| Distilled water | ????108±36 | ||
| Embodiment 1 | ????450 | ????304±31 | ????＜0.001 |
| Embodiment 1 | ????300 | ????282±30 | ????＜0.001 |
| Aminophylline | ????25 | ????327±29 | ????＜0.001 |
Table 2 explanation, embodiment 1 and aminophylline all can prolong to draw very significantly to be breathed heavily incubation period.Embodiment 1 is tangible dose-effect relationship.
Three, the influence of 1 pair of Guinea pig lung perfusion of embodiment
1. be prepared in advance lung, bronchus perfusion device are full of oxygen containing locke solution in the reservoir, the coil in the water-bath of constant temperature (37 ℃) arrives perfusion cannula, and the bottom of reservoir exceeds the about 50cm of level.
2. get 32 of 400-500g Cavia porcelluss, be divided into four groups at random, every group 8, male and female have concurrently, get trachea and the whole lung of every Cavia porcellus during experiment respectively, in the culture dish that contains the oxygen locke solution with 37 ℃ of lung immersions, defend lung gently for several times, to discharge gas in the lung, the reuse syringe is inhaled locke solution 5ml, in trachea injects lung, makes atelectasis, be tied in trachea on the sleeve pipe of perfusion device with line then, open also take off square folder, with the locke solution perfusion it, on the surface of lung with 16 of being dispersed in property of syringe needle perforation, speed so that the height of regulating storage liquid is regulated perfusion makes the about 30ml of per minute discharge.
3. after treating that perfusion flow is constant, record per minute flow gets final product administration, injects medicinal liquid in the rubber tube by cannula tip: (1) 30% embodiment 1 leachate 0.5ml, per minute discharge in half a minute opening entry 10 minutes after the medication.(2) 0.01% histamine liquid 0.5ml, half a minute opening entry per minute discharge after the medication, and the rush hour and the persistent period of observing its effect.(3) repeat to inject histamine, treat it after 5 minutes, give 30% embodiment 1 leachate 0.5ml, observe the variation of perfusion flow, experimental result is listed table 3, table 4, table 5 respectively in.
The influence of 1 pair of Guinea pig lung perfusion flow of table 3. embodiment
| Flow (ml/ branch) before the administration | Flow after the administration (ml/ branch) | |||||||||||
| 1' | ??2' | ??3' | ?1' | ????2' | ??3' | ????4' | ???5' | ????6' | ????7' | ???8' | ????9' | ??10' |
| 20.1 ± 1.4 | ?20.1 ?± ?1.5 | ?20.0 ?± ?1.3 | ?20.2 ?± ?1.9 | ??20.9 ??± ?1.8 | ?22.4 ?± ?1.8 | ??23.0 ??± ??2.3 | ?24.8 ?± ?3.2 | ?26.0 ?± ?4.1 | 28.0 ± 4.6 | ?31.0 ?± ?4.8 | ?34.1 ?± ?5.6 | ?36.1 ?± ?5.9 |
Table 4. histamine is to the influence of Guinea pig lung perfusion flow
| Flow (ml/ branch) before the administration | Flow after the administration (ml/ branch) | |||||||||||
| 1' | 2' | 3' | ????1' | 2' | 3' | 4' | 5' | 6' | ?7' | ??8' | ????9' | ??10' |
| 21.2 ± 2.8 | ?21.6 ?± ?2.7 | ?21.8 ?± ?2.6 | ?21.8 ????± ????2.5 | ?20.4 ?± ?2.1 | 18.8 ± 2.2 | ?18.4 ?± ?1.9 | ?17.8 ?± ?1.8 | 17.5 ± 2.1 | 17.2 ± 2.0 | ?17.1 ?± ?1.8 | ?16.8 ?± ?1.7 | ?17.0 ?± ?1.8 |
The influence of Guinea pig lung perfusion flow due to 1 pair of antihistamine of table 5. embodiment
From last table result as seen, embodiment 1 can improve the lung perfusion flow of normal guinea pig, and the Guinea pig lung perfusion flow that can resist due to the amine descends.Give embodiment in the time of 1 three minutes, relatively, have significant difference (p＜0.01) before discharge and the medication.
| To flow (ml/ branch) behind the histamine | Flow after the administration (ml/ branch) | |||||||||
| ????5' | ????1' | ????2' | ???3' | ?4' | 5' | ?6' | 7' | 8' | 9' | ?10' |
| ????17.0 ??????± ???? ??????????1.7 | ??17.8 ????± ???? ??????1.8 | ?18.2 ??± ??1.9 | ?21.0 ?± ??2.3 | ?22.6 ?± ??2.7 | ?23.5 ?± ??2.6 | ?25.0 ?± ??2.9 | 27.3 ± ??3.5 | ?29.1 ?± ??4.3 | ?31.1 ?± ??5.1 | ?34.0 ?± ??4.8 |
Four, embodiment 1 acute toxicity test
Press the Bliss method and calculate, the acute toxicity testing result is: the oral LD50 of embodiment 1 mice is 4.552 ± 0.226g/kg.Be the once maximum dosage of adult (4.5g/50kg=0.09g/kg) 50 times.Show that embodiment 1 one has the medicine of excellent safety.
Bronchial asthma is bronchial muscular spasm and the obstructive respiration difficulty that produces.Thereby the releasing bronchospasm is its important treatment measure.
Experimental result shows, the Cavia porcellus asthma due to 1 pair of histamine of embodiment has significant antagonism; The guinea pig trachea that exsomatizes there is tangible diastole effect; Guinea pig lung bronchus filling amount decline due to the histamine there is significant antagonism.These act as embodiment 1 treatment bronchial asthma experimental basis are provided.
Embodiment 1 is through clinical observation, shows that its instant effect of relievining asthma, the time of relievining asthma are long, and physical rehabilitation is fast.Bronchial asthma, anaphylaxis, the twin property of convulsion, asthma such as congenital all there is good therapeutic effect.
Other embodiments of the invention our experiments show that with embodiment 1 similar drug effect, toxicity result and clinical efficacy.
The invention is not restricted to the foregoing description.
Claims (7)
1. treating asthma medicine, it is characterized in that it is the pharmaceutical dosage form of being made by following medicine: Folium Elaeagni, Cacumen Platycladi, Folium Viticis Negundo, Caulis Perillae, Radix Ginseng, Lignum Aquilariae Resinatum, Rhizoma Dioscoreae, Radix Glycyrrhizae, Bulbus Fritillariae Cirrhosae, Cortex Magnoliae Officinalis, Ramulus Cinnamomi, Radix Et Rhizoma Rhei, wherein the ratio of each medicine is for being 1 weight portion with a medicine in the prescription, and all the other amount of drug are 1/5～5 times of weight portion.
2. a kind for the treatment of asthma medicine according to claim 1 is characterized in that weight fraction such as described each medicine.
3. a kind for the treatment of asthma medicine according to claim 1 and 2 is characterized in that Bulbus Fritillariae Cirrhosae replaces with Bulbus Fritillariae Thunbergii.
4. a kind for the treatment of asthma medicine according to claim 1 and 2 is characterized in that said pharmaceutical dosage form is a said peroral dosage form on any pharmaceutics.
5. according to claim 1,2,3 described a kind for the treatment of asthma medicines, it is characterized in that said pharmaceutical dosage form is a powder.
6. according to claim 1,2,3 described a kind for the treatment of asthma medicines, it is characterized in that said pharmaceutical dosage form is an oral liquid.
7. the described a kind for the treatment of asthma medicine production method of claim 5, it is characterized in that getting Folium Elaeagni, Cacumen Platycladi, Folium Viticis Negundo, Caulis Perillae, Radix Ginseng, Lignum Aquilariae Resinatum, Rhizoma Dioscoreae, Radix Glycyrrhizae, Bulbus Fritillariae Cirrhosae, Cortex Magnoliae Officinalis, Ramulus Cinnamomi, each medicine full dose of Radix Et Rhizoma Rhei, grinding and processing becomes powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114245 CN1105563C (en) | 2000-05-10 | 2000-05-10 | Asthma treating medicine and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114245 CN1105563C (en) | 2000-05-10 | 2000-05-10 | Asthma treating medicine and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1299656A true CN1299656A (en) | 2001-06-20 |
| CN1105563C CN1105563C (en) | 2003-04-16 |
Family
ID=4583951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00114245 Expired - Fee Related CN1105563C (en) | 2000-05-10 | 2000-05-10 | Asthma treating medicine and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1105563C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315505C (en) * | 2003-04-21 | 2007-05-16 | 罗大义 | Formula of Chinese traditional medicine curing cough and asthma |
| US7384654B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-Allergy composition and related method |
| CN109512967A (en) * | 2019-01-25 | 2019-03-26 | 张掖市金盛中药饮片有限公司 | A kind of Chinese patent drug and preparation method thereof for treating asthma |
-
2000
- 2000-05-10 CN CN 00114245 patent/CN1105563C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315505C (en) * | 2003-04-21 | 2007-05-16 | 罗大义 | Formula of Chinese traditional medicine curing cough and asthma |
| US7384654B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-Allergy composition and related method |
| US7384656B2 (en) | 2004-02-05 | 2008-06-10 | Access Business Group International Llc | Anti-allergy composition and related method |
| CN109512967A (en) * | 2019-01-25 | 2019-03-26 | 张掖市金盛中药饮片有限公司 | A kind of Chinese patent drug and preparation method thereof for treating asthma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1105563C (en) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1098695C (en) | Chinese medicinal composition for treating asthma and preparing process thereof | |
| CN1105563C (en) | Asthma treating medicine and its production process | |
| CN103622947A (en) | Application of anhydroicaritin in preparation of drugs used for treating asthma | |
| CN100998811A (en) | Orally taken Chinese medicine for treating accumulation of phlegm and heat in type bronchitis | |
| CN1111059C (en) | Medicine for treating asthma | |
| CN1088817A (en) | The Chinese medicine preparation of treatment tracheitis is coughed rather | |
| CN1234254A (en) | Health-care drink of relieving cough and asthma | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1293903C (en) | Fant calming powder injection and its preparation method | |
| CN113694100A (en) | Pharmaceutical composition for treating chronic obstructive pulmonary disease and silicosis and application thereof | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN101007123B (en) | Medicinal composition for treating and relieving rhinitis | |
| CN1839953A (en) | Medicine for treating idiopathy thrombocytopenia peliosis | |
| CN104644656A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating asthma and medicament | |
| CN1218718C (en) | Medication for bronchial asthma and chronic bronchitis , and its preparation method | |
| CN1504212A (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN1891281A (en) | Chinese medicine preparation for treating wind-cold disease, and its preparing method | |
| CN1634340A (en) | A pharmaceutical composition for preventing and treating children's respiratory diseases and its preparation method | |
| CN1055239C (en) | Plaster for curing cough and asthma and its producing method | |
| CN1178690C (en) | Medicine for regulating immunity and its production method | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN1211100C (en) | Compound combined medicine for giving up drug | |
| CN1720936A (en) | Medicine for treating breadth gasp, cough, asthma and phelgm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030416 Termination date: 20160510 |